Table 3.

Prespecified definitions for medication use at baseline

Medication	ATC codes	Number of prescriptions	Timeframe
Antithrombotics	B01	≥ 1 claimed prescription	≤ 180 days prior to randomization
Renin-angiotensin system inhibitor	C09	≥ 1 claimed prescription	≤ 180 days prior to randomization
Calcium blockers	C08	≥ 1 claimed prescription	≤ 180 days prior to randomization
Beta blockers	C07	≥ 1 claimed prescription	≤ 180 days prior to randomization
Diuretics	C03	≥ 1 claimed prescription	≤ 180 days prior to randomization
Aspirin	B01AC06	≥ 1 claimed prescription	≤ 180 days prior to randomization
Statins	C10AA	≥ 1 claimed prescription	≤ 180 days prior to randomization
Inhaled beta-2 agonists	R03A	≥ 1 claimed prescription	≤ 180 days prior to randomization
Inhaled anticholinergics	R03BB, R03AL01-07	≥ 1 claimed prescription	≤ 180 days prior to randomization
Inhaled glucocorticoids	R03BA, R03AK, R03AL08-09, R03AL11-12	≥ 1 claimed prescription	≤ 180 days prior to randomization
Insulin	A10A	≥ 1 claimed prescription	≤ 180 days prior to randomization
Non-insulin antidiabetic medication	A10B	≥ 1 claimed prescription	≤ 180 days prior to randomization
Systemic glucocorticoids	H02AB	≥ 1 claimed prescription	≤ 180 days prior to randomization
Immunosuppres-sants	L04	≥ 1 claimed prescription	≤ 180 days prior to randomization

Medication use at baseline will be assessed using ATC codes. ATC anatomic therapeutical chemical